Trials / Completed
CompletedNCT04218162
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate Efficacy and Safety of Lasmiditan Compared to Placebo in the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 294 (actual)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lasmiditan 50mg | Lasmiditan 50mg |
| DRUG | Lasmiditan 100mg | Lasmiditan 100mg |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2020-03-24
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
- First posted
- 2020-01-06
- Last updated
- 2021-04-01
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04218162. Inclusion in this directory is not an endorsement.